A Phase l Open-Label, Dose Escalation and Cohort Expansion Study, to Assess the Safety and Activity of the Antibody-Drug Conjugate CDX-014 in Advanced or Metastatic Renal Cell Carcinoma (RCC) and Advanced or Metastatic Ovarian Clear Cell Carcinoma (OCCC)

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CDX 014 (Primary)
Indications Carcinoma; Ovarian cancer; Renal cell carcinoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Celldex Therapeutics Inc

Most Recent Events

29 May 2020 Results assessing safety and preliminary activity of CDX-014 in patients with advanced refractory renal cell carcinoma, published in the Investigational New Drugs.
20 Nov 2018 Status changed from active, no longer recruiting to discontinued.
11 May 2018 Planned End Date changed from 1 Aug 2020 to 1 Oct 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight